US · NBIX · BIOTECHNOLOGY
Neurocrine Biosciences, Inc. (NBIX) intrinsic value and stock valuation
$150.57as of 2026-11-21 · Mkt cap 16.24B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Neurocrine Biosciences, Inc. DCF and intrinsic value
InvestorsCraft values NBIX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NBIX’s statements →
Neurocrine Biosciences, Inc. Graham Number
Graham Number: $59.48d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Viatris Inc. (VTRS) $19.63
- The Cooper Companies, Inc. (COO) $58.88
- Elanco Animal Health Incorporated (ELAN) $25.74
- Smith & Nephew plc (SNN) $29.83
- ICON Public Limited Company (ICLR) $186.71
- Summit Therapeutics Inc. (SMMT) $9.95
- Universal Health Services, Inc. (UHS) $179.43
- Dr. Reddy's Laboratories Limited (RDY) $14.89
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Operating income | $619.1M | $570.5M | $250.9M | $249M | $102.5M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M |
| EPSd | $4.67M | $3.29M | $2.47M | $1.56M | $915.2K |
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M |
| Capital expenditure | -$-34M | -$-38.2M | -$-28.3M | -$-16.5M | -$-23.4M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M |
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B |
| Total debt | $415.3M | $455.1M | $428.4M | $262.9M | $440.4M |
| Net debt | -$-297.7M | $222.1M | $177.3M | $0.00 | $99.6M |
| Total equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B |
| Cash and short-term investments | $1.48B | $1.08B | $1.03B | $989.3M | $711.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Cost of revenue | $52.1M | $34M | $39.7M | $23.2M | $14.3M |
| Gross profit | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B |
| Research and development expenses | $1.02B | $731.1M | $565M | $463.8M | $328.1M |
| Selling, general and administrative expenses | $1.16B | $1.01B | $887.6M | $752.7M | $583.3M |
| Other expenses | $17.4M | $12.5M | $143.9M | $0.00 | $105.3M |
| Operating expenses | $2.19B | $1.75B | $1.6B | $1.22B | $1.02B |
| Cost and expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B |
| Interest income | $90.3M | $91M | $0.00 | $11.2M | $0.00 |
| Interest expense | $0.00 | $126.6M | $4.6M | $7.1M | $25.8M |
| Depreciation and amortization | $30.1M | $27.1M | $21.3M | $15.6M | $10.9M |
| Ebitda | $666.6M | $639.7M | $416.1M | $236.6M | $138.1M |
| Operating income | $619.1M | $570.5M | $250.9M | $249M | $102.5M |
| Total other income/expenses, net | $86.3M | -$-84.5M | $81.2M | -$-35.1M | -$-1.1M |
| Income before tax | $705.4M | $486M | $332.1M | $213.9M | $101.4M |
| Income tax expense | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M |
| Weighted average shares outstanding | $99.5M | $100.4M | $97.7M | $95.8M | $94.6M |
| Weighted average diluted shares outstanding | $102.5M | $103.7M | $101M | $98.9M | $97.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.48B | $1.08B | $1.03B | $989.3M | $711.3M |
| Net receivables | $686.8M | $479.1M | $439.3M | $350M | $185.5M |
| Inventory | $69M | $57.4M | $38.3M | $35.1M | $30.5M |
| Total current assets | $2.52B | $1.72B | $1.61B | $1.45B | $972.8M |
| Property, plant and equipment, net | $545.2M | $592M | $347.3M | $145.6M | $155.8M |
| Goodwill and intangible assets | $0.00 | $36.5M | $35.5M | $37.2M | $0.00 |
| Long-term investments | $1.18B | $864.3M | $849.4M | $401.5M | $624.4M |
| Total non-current assets | $2.11B | $1.99B | $1.64B | $915.2M | $1.1B |
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B |
| Accounts payable | $104.9M | $99.9M | $133.3M | $67.3M | $51.5M |
| Short-term debt | $0.00 | $0.00 | $170.1M | $169.4M | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $743.4M | $507.7M | $654.8M | $537.7M | $245.8M |
| Long-term debt | $415.3M | $455.1M | $258.3M | $93.5M | $440.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $635M | $621.3M | $364.6M | $123.2M | $452.7M |
| Capital lease obligations | $415.3M | $455.1M | $258.3M | $93.5M | $105.3M |
| Total liabilities | $1.38B | $1.13B | $1.02B | $660.9M | $698.5M |
| Common stock | $100K | $100K | $100K | $100K | $100K |
| Retained earnings | $447.7M | $29.2M | -$-157.1M | -$-406.8M | -$-635.8M |
| Accumulated other comprehensive income (loss) | $13.1M | $5.8M | $7M | -$-7.9M | -$-1.7M |
| Total equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B |
| Total investments | $1.95B | $1.71B | $1.63B | $1.13B | $994.9M |
| Total debt | $415.3M | $455.1M | $428.4M | $262.9M | $440.4M |
| Net debt | -$-297.7M | $222.1M | $177.3M | $0.00 | $99.6M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M |
| Depreciation and amortization | $30.1M | $27.1M | $21.3M | $15.6M | $10.9M |
| Stock-based compensation | $217.9M | $195.5M | $194.3M | $173.1M | $134.2M |
| Change in working capital | -$-128.8M | -$-19.2M | $28.2M | -$-67.4M | $16.7M |
| Accounts receivable | -$-210.5M | -$-39.8M | -$-89.3M | -$-162.2M | -$-28.4M |
| Inventory | -$-15.3M | -$-19.1M | $5.4M | -$-2.6M | -$-2.5M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M |
| Investments in property, plant and equipment | -$-34M | -$-38.2M | -$-28.3M | -$-16.5M | -$-23.4M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-42.7M | $0.00 |
| Net cash used for investing activities | -$-264.4M | -$-126.8M | -$-467.1M | -$-177.1M | -$-130.2M |
| Common stock issued | $129.4M | $122.1M | $65.3M | $44.7M | $27.5M |
| Common stock repurchased | -$-167.7M | -$-300M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-38.3M | -$-486.7M | $65.3M | -$-234.3M | $27.4M |
| Net change in cash | $480M | -$-18.1M | -$-11.6M | -$-73.3M | $153.7M |
| Cash at end of period | $721M | $241M | $259.1M | $270.7M | $344M |
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M |
| Capital expenditure | -$-34M | -$-38.2M | -$-28.3M | -$-16.5M | -$-23.4M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M |
Line items
Line items
Line items
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
- CEO
- Kyle W. Gano
- Employees
- 2K
- Beta
- 0.39
Explore
Frequently asked questions
What is the intrinsic value of Neurocrine Biosciences, Inc. (NBIX)?
Neurocrine Biosciences, Inc. (NBIX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NBIX undervalued?
NBIX trades at a price of $150.57 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.